## Abstract ## Purpose To assess the safety data from two large, multicenter, phase 2 trials on the use of gadoversetamide (OptiMARK, Tyco Healthcare/Mallinckrodt, St. Louis, MO) as a contrast agent in delayed hyperenhancement magnetic resonance imaging (DEβMRI) in patients with acute and chronic
Comparison of 3D and 2D acquisition of late gadolinium enhancement in patients with acute, subacute and chronic myocardial infarction
β Scribed by Robert Goetti; Sebastian Kozerke; Olivio F Donati; Paul Stolzmann; Roberto Corti; Robert Manka
- Publisher
- BioMed Central
- Year
- 2011
- Tongue
- English
- Weight
- 408 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1097-6647
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Purpose To investigate myocardial infarction (MI), late gadolinium (Gd) enhancement (LGE), cardiovascular magnetic resonance imaging (CMRI) is used as the current gold standard for the in vivo diagnosis in patients and preclinical studies. While inversion recovery (IR) fast gradient
Tanimoto et al.: Assessment of myocardial viability in low signal intensity areas on cine MRI comparison with late gadolinium enhancement imaging in patients with prior myocardial infarction.
To quantify myocardial injury in patients with acute STelevation myocardial infarcts (STEMI) by T1-mapping using Shortened Modified Look-Locker Inversion Recovery (ShMOLLI).